Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Cancer Discovery|June 13, 2015
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesFerdinandos Skoulidis, Lauren A Byers, Lixia Diao, et al.
Research Square|July 28, 2023
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockadeErez N Baruch, Priyadahrshini Nagarajan, Frederico O Gleber-Netto, et al.
Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
The Journal of Experimental Medicine|November 11, 2022
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltrationYifan Zhou, Yusra B Medik, Bhakti Patel, et al.
Nature Communications|February 1, 2020
Comprehensive T cell repertoire characterization of non-small cell lung cancerAlexandre Reuben, Jiexin Zhang, Shin-Heng Chiou, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Cancer Discovery|June 13, 2015
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesFerdinandos Skoulidis, Lauren A Byers, Lixia Diao, et al.
Research Square|July 28, 2023
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockadeErez N Baruch, Priyadahrshini Nagarajan, Frederico O Gleber-Netto, et al.
Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
The Journal of Experimental Medicine|November 11, 2022
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltrationYifan Zhou, Yusra B Medik, Bhakti Patel, et al.
Nature Communications|February 1, 2020
Comprehensive T cell repertoire characterization of non-small cell lung cancerAlexandre Reuben, Jiexin Zhang, Shin-Heng Chiou, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Pageof 21